— Know what they know.
Not Investment Advice

CLYM NASDAQ

Climb Bio, Inc.
1W: -6.2% 1M: -27.3% 3M: -17.6% YTD: +191.7% 1Y: +455.3%
$10.94
-0.13 (-1.17%)
 
Weekly Expected Move ±8.9%
$9 $10 $11 $12 $13
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 31 · $626.5M mcap · 49M float · 2.91% daily turnover · Short 48% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
37.6 / 100
NoneWeakNarrowWide
Primary source: Switching Costs  ·  ROIC: -88.6%
Cost Advantage
33
Intangibles
25
Switching Cost
60
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. CLYM has No discernible competitive edge (37.6/100). The business operates without significant structural advantages. The primary source of advantage is Switching Costs. Negative ROIC of -88.6% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$24
Low
$29
Avg Target
$40
High
Based on 7 analysts since Aug 6, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 7Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$28.00
Analysts8
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-09-08 Oppenheimer — Initiated $25 — +62.8% $15.36
2026-09-08 H.C. Wainwright — $24 $30 +6 +93.3% $15.52
2026-09-03 BTIG — $20 $32 +12 +118.1% $14.67
2026-09-03 Robert W. Baird — $21 $25 +4 +71.0% $14.62
2026-09-03 Piper Sandler Yasmeen Rahimi Initiated $40 — +176.6% $14.46
2026-08-24 H.C. Wainwright — $20 $24 +4 +38.9% $17.28
2026-08-07 Truist Financial — $17 $25 +8 +79.9% $13.90
2026-08-03 RBC Capital Nevin Varghese Initiated $23 — +93.3% $11.90
2026-06-11 BTIG Julian Harrison Initiated $20 — +79.1% $11.17
2026-06-08 Guggenheim — Initiated $35 — +231.8% $10.55
2026-05-12 H.C. Wainwright Raghuram Selvaraju $11 $20 +9 +79.9% $11.12
2026-05-08 Wedbush — Initiated $17 — +40.9% $12.06
2026-05-06 Robert W. Baird — Initiated $21 — +83.4% $11.45
2026-05-05 Chardan Capital — Initiated $22 — +127.0% $9.69
2026-04-15 Mizuho Securities Joseph Catanzaro Initiated $18 — +103.4% $8.85
2026-03-17 Truist Financial Danielle Brill Initiated $17 — +138.8% $7.12
2026-03-10 Raymond James Christopher Raymond Initiated $25 — +241.1% $7.33
2025-12-18 H.C. Wainwright Raghuram Selvaraju Initiated $11 — +158.8% $4.25

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
Oct 02, 2026
DCF
3
ROE
1
ROA
1
D/E
2
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. CLYM receives an overall rating of C. Areas of concern: ROE (1/5), ROA (1/5), D/E (2/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-10-01 C+ C
2026-05-14 C C+
2026-05-11 C+ C
2026-04-24 C C+
2026-04-16 C+ C
2026-04-13 C C+
2026-04-01 C+ C
2026-03-06 B- C+
2026-01-06 B B-
2026-01-05 B- B

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+
Profitability
—
Balance Sheet
85
Earnings Quality
66
Growth
—
Value
36
Momentum
—
Safety
100
Cash Flow
—

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
86.59
Safe Zone
Piotroski F-Score
2/9
✗ ✗ ✗ ✓ ✗ ✓ ✗ ✗ ✗
Beneish M-Score
—
—
Ohlson O-Score
5.12
Bankruptcy prob: 99.4%
High Risk
Credit Rating
A+
Score: 75.7/100
Trend: Stable
Earnings Quality
—
OCF/NI: 0.91x
Accruals: -2.2%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. CLYM scores 86.59, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. CLYM scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. CLYM's implied 99.4% bankruptcy probability signals significant financial distress. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. CLYM receives an estimated rating of A+ (score: 75.7/100), with a stable trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-13.18x
PEG
0.65x
P/S
0.00x
P/B
3.48x
P/FCF
-18.71x
P/OCF
—
EV/EBITDA
-13.67x
EV/Revenue
—
EV/EBIT
-13.64x
EV/FCF
-15.29x
Earnings Yield
-5.80%
FCF Yield
-5.34%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. CLYM currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
0.969
EBT / EBIT
×
EBIT Margin
—
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.031
Assets / Equity
=
ROE
-27.1%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. CLYM's ROE of -27.1% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 519 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$10.94
Median 1Y
$8.75
5th Pctile
$1.91
95th Pctile
$40.09
Ann. Volatility
88.0%
Analyst Target
$28.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -4.1% -8.2% -19.7% -25.2% -25.6% -32.1% -30.9% -27.1% -27.10%
ROA -4.0% -8.0% -19.0% -24.3% -25.1% -31.1% -29.9% -26.3% -26.27%
ROIC -36.4% -29.1% -37.7% -43.8% -51.8% -89.5% -1.2% -88.6% -88.61%
ROCE -5.4% -10.7% -23.6% -29.2% -31.3% -38.6% -35.6% -24.7% -24.75%
Gross Margin — — — — — — — — —
Operating Margin — — — — — — — — —
Net Margin — — — — — — — — —
EBITDA Margin — — — — — — — — —
FCF Margin — — — — — — — — —
OCF Margin — — — — — — — — —
ROIC Economic snapshot only -21.24%
Cash ROA snapshot only -21.40%
Cash ROIC snapshot only -91.27%
CROIC snapshot only -91.91%
Valuation
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -38.35 -6.73 -2.16 -1.79 -2.69 -4.50 -8.85 -17.23 -13.181
P/S Ratio — — — — — — — — 0.000
P/B Ratio 1.56 0.55 0.43 0.45 0.77 1.68 3.16 4.15 3.478
P/FCF -45.15 -8.91 -2.89 -2.11 -3.08 -4.94 -8.74 -18.71 -18.713
P/OCF — — — — — — — — —
EV/EBITDA -12.60 1.50 0.33 0.00 -0.91 -2.73 -6.80 -13.67 -13.668
EV/Revenue — — — — — — — — —
EV/EBIT -12.60 1.50 0.33 0.00 -0.91 -2.72 -6.78 -13.64 -13.638
EV/FCF -19.56 2.59 0.54 0.01 -1.13 -3.10 -6.70 -15.29 -15.287
Earnings Yield -2.6% -14.9% -46.3% -55.8% -37.1% -22.2% -11.3% -5.8% -5.80%
FCF Yield -2.2% -11.2% -34.6% -47.4% -32.5% -20.2% -11.4% -5.3% -5.34%
PEG Ratio snapshot only 0.649
Price/Tangible Book snapshot only 4.146
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 57.73 31.41 14.25 14.08 18.38 15.16 27.86 31.45 31.452
Quick Ratio 57.73 31.41 14.25 14.08 18.38 15.16 27.86 31.45 31.452
Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.005
Net Debt/Equity -0.88 -0.71 -0.50 -0.45 -0.49 -0.63 -0.74 -0.76 -0.759
Debt/Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.005
Debt/EBITDA -0.00 -0.02 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.022
Net Debt/EBITDA 16.48 6.64 2.14 1.55 1.56 1.62 2.07 3.06 3.063
Interest Coverage — — — — — — — — —
Equity Multiplier 1.02 1.03 1.04 1.04 1.03 1.05 1.03 1.03 1.028
Cash Ratio snapshot only 30.860
Cash to Debt snapshot only 139.363
FCF to Debt snapshot only -40.387
Defensive Interval snapshot only 1033.2 days
Efficiency & Turnover
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Inventory Turnover — — — — — — — — —
Receivables Turnover 0.00 0.00 0.00 — 0.00 0.00 0.00 — —
Payables Turnover 0.00 0.00 0.00 0.04 0.10 0.05 0.13 0.07 0.065
DSO — — — — — — — — —
DIO — — — 0 0 0 0 0 0.0 days
DPO — — — 9087 3688 7982 2818 5580 5579.7 days
Cash Conversion Cycle — — — — — — — — —
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue — — — — — — — — —
Net Income — — — — -4.7% -2.5% -38.6% -23.2% -23.24%
EPS — — — — -4.6% -2.3% -37.1% -9.4% -9.37%
FCF — — — — -4.9% -3.2% -87.6% -33.6% -33.55%
EBITDA — — — — -3.7% -1.7% -15.3% -9.3% -9.33%
Op. Income — — — — -4.1% -2.0% -31.6% -14.9% -14.95%
OCF Growth snapshot only -32.88%
Asset Growth snapshot only 28.02%
Equity Growth snapshot only 28.95%
Debt Growth snapshot only 1.06%
Shares Change snapshot only 12.68%
Growth Quality
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability — — — — — — — — —
Earnings Stability — — — — — — — — —
Margin Stability — — — — — — — — —
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0
Earnings Persistence — — — — — — — — —
Earnings Smoothness — — — — — — — — —
ROE Trend — — — — — — — — —
Gross Margin Trend — — — — — — — — —
FCF Margin Trend — — — — — — — — —
Sustainable Growth Rate — — — — — — — — —
Internal Growth Rate — — — — — — — — —
Cash Flow Quality
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.85 0.76 0.75 0.85 0.87 0.91 1.01 0.91 0.915
FCF/OCF 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.01 1.007
FCF/Net Income snapshot only 0.921
CapEx/Revenue — — — — — — — — —
CapEx/Depreciation snapshot only 2.838
Accruals Ratio -0.01 -0.02 -0.05 -0.04 -0.03 -0.03 0.00 -0.02 -0.022
Sloan Accruals snapshot only 0.453
Cash Flow Adequacy snapshot only -142.816
Dividends & Buybacks
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — —
FCF Payout Ratio — — — — — — — — —
Total Payout Ratio — — — — — — — — —
Div. Increase Streak — — — — — — — — —
Chowder Number — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -0.7% -2.0% -2.8% -2.8% -0.0% -0.0% -0.0% -10.4% -10.44%
Total Shareholder Return -0.7% -2.0% -2.8% -2.8% -0.0% -0.0% -0.0% -10.4% -10.44%
DuPont Factors
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 0.76 0.76 0.83 0.86 0.91 0.96 1.00 0.97 0.969
EBIT Margin — — — — — — — — —
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Equity Multiplier 1.02 1.03 1.04 1.04 1.02 1.03 1.03 1.03 1.031
Per Share
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.13 $-0.27 $-0.56 $-0.69 $-0.75 $-0.89 $-0.77 $-0.76 $-0.76
Book Value/Share $3.26 $3.27 $2.87 $2.75 $2.60 $2.38 $2.17 $3.15 $3.15
Tangible Book/Share $3.26 $3.27 $2.87 $2.75 $2.60 $2.38 $2.17 $3.15 $3.15
Revenue/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-0.11 $-0.20 $-0.42 $-0.59 $-0.65 $-0.81 $-0.78 $-0.70 $-0.70
OCF/Share $-0.11 $-0.20 $-0.42 $-0.59 $-0.65 $-0.81 $-0.78 $-0.69 $-0.69
Cash/Share $2.89 $2.33 $1.45 $1.25 $1.28 $1.50 $1.61 $2.40 $2.40
EBITDA/Share $-0.18 $-0.35 $-0.68 $-0.80 $-0.81 $-0.92 $-0.77 $-0.78 $-0.78
Debt/Share $0.00 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 $0.02 $0.02
Net Debt/Share $-2.88 $-2.32 $-1.45 $-1.24 $-1.27 $-1.49 $-1.60 $-2.39 $-2.39
Academic Models
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — 86.592
Altman Z-Prime snapshot only 153.538
Piotroski F-Score 2 2 2 2 1 1 1 2 2
Beneish M-Score — — — — — — — — —
Ohlson O-Score snapshot only 5.122
ROIC (Greenblatt) snapshot only -32.57%
Net-Net WC snapshot only $2.36
EVA snapshot only $-56932620.00
Credit
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only A+
Credit Score 76.07 76.11 76.01 76.16 75.85 75.71 75.74 75.70 75.703
Credit Grade snapshot only 5
Credit Trend snapshot only -0.460
Implied Spread (bps) snapshot only 125.000
Industry Credit Rank snapshot only 76
Sector Credit Rank snapshot only 71

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms